DIABS & NUTRICARE

24/08/2024

20/08/2024

A large retrospective study of electronic medical records found better cardiovascular and renal outcomes in patients with type 2 diabetes treated with tirzepatide vs GLP-1 RAs.

09/09/2023

The investigational siRNA therapeutic showed consistent and sustained reductions in systolic blood pressure in a phase 2 study of adults with hypertension.

09/08/2023

Top-line results show semaglutide for weight loss (Wegovy) cut cardiovascular events in the 17,000-person SELECT CV outcomes trial, which should reframe the health benefit of this weight loss drug.

04/03/2023

Stay current on FDA drug approvals in 2023

02/03/2023

In randomized trial, the old cardiac agent slowed the destruction of insulin-producing beta cells in youth with new-onset type 1 diabetes.

01/03/2023

De astăzi, oferim pacienților noi investigații: determinarea indexului Gleznă/Braț, pentru detectarea modificărilor circulatorii arteriale la nivelul membrelor inferioare (serviciu decontat prin casa de asigurări), respectiv determinarea compoziției masei corpului/rata metabolica bazală cu ajutorul cantarului Tanita ( serviciu medical cu plată!

23/01/2023

Another SGLT2 inhibitor has been approved for type 2 diabetes based on results from 23 clinical trials that included 5000 patients and more than 300 patients who also had stage 3 chronic kidney disease.

27/09/2022

A novel triple agonist targeting the GIP, GLP-1, and glucagon receptors produced unprecedented weight loss in patients with type 2 diabetes after 12 weeks on treatment in a safety study.

30/04/2022

Survival of patients with type 2 diabetes and CVD rose by 80% when they received both an SGLT2 inhibitor and GLP-1 RA, compared with either class alone.

30/04/2022

The once-weekly investigational twincretin drug is in phase 3 development for obesity and under regulatory review, with a decision expected soon for type 2 diabetes.

21/04/2020

Va rugam ca în această perioadă a starii de urgenta, să ne contactați pe nr. de telefon afișat sau pe adresa de e-mail, în vederea evitării deplasării. Consultațiile se pot efectua telefonic iar investigațiile pot fi trimise pe adresa de e-mail. Rețele pot fi trimise pe adresa Dvs de e-mail sau prin intermediul whatsapp. Să ne revedem sănătoși.


0372951227
Dr.pena76@gmail.com

03/04/2020

În vederea limitării deplasării pacienților, se poate solicita eliberarea rețetei și transmiterea acesteia pe email.Adresa de email la care puteți face solicitarea este dr.pena76@gmail.com.
Dr. Cosmin Pena